Comparative Pharmacology
Head-to-head clinical analysis: EPICORT versus LOCOID LIPOCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPICORT versus LOCOID LIPOCREAM.
EPICORT vs LOCOID LIPOCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
IV: 50 mg every 8 hours over 30 minutes.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
None Documented
None Documented
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid